← Back to Screener
Amgen Inc (AMGN)
Price$350.16
Favorite Metrics
Price vs S&P 500 (26W)13.72%
Price vs S&P 500 (4W)-7.34%
Market Capitalization$191.15B
P/E Ratio (Annual)24.79x
Indicated Dividend Yield (Annual)2.84%
All Metrics
P/CF (Annual)19.20x
Book Value / Share (Quarterly)$16.06
P/TBV (Annual)24.53x
Indicated Dividend (Annual)$9.52
Revenue Growth (3Y)11.77%
Cash Flow / Share (Quarterly)$15.03
Payout Ratio (TTM)72.03%
Price vs S&P 500 (YTD)4.41%
Gross Margin (TTM)73.30%
Net Profit Margin (TTM)20.98%
EPS (TTM)$14.23
10-Day Avg Trading Volume2.56M
EPS Excl Extra (TTM)$14.23
Revenue Growth (5Y)7.65%
EPS (Annual)$14.23
Dividend / Share (Annual)$9.01
ROI (Annual)12.19%
Gross Margin (Annual)82.52%
Net Profit Margin (5Y Avg)20.92%
Cash / Share (Quarterly)$16.94
P/E Basic Excl Extra (TTM)24.79x
Revenue Growth QoQ (YoY)8.58%
EPS Growth (5Y)2.93%
P/E Normalized (Annual)24.79x
ROA (Last FY)8.51%
Revenue Growth TTM (YoY)9.95%
EBITD / Share (TTM)$25.26
ROE (5Y Avg)106.67%
Operating Margin (TTM)25.43%
Cash Flow / Share (Annual)$15.03
P/B Ratio22.08x
P/B Ratio (Quarterly)20.36x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)6.44x
Net Interest Coverage (TTM)13.26x
ROA (TTM)8.62%
EPS Growth QoQ (YoY)111.81%
EV / EBITDA (TTM)17.29x
EPS Incl Extra (Annual)$14.23
Current Ratio (Annual)1.14x
Quick Ratio (Quarterly)0.90x
3-Month Avg Trading Volume2.80M
52-Week Price Return25.71%
EV / Free Cash Flow (Annual)29.21x
P/E Incl Extra (TTM)24.79x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$7.09
P/S Ratio (Annual)5.20x
Asset Turnover (Annual)0.41x
52-Week High$391.29
Operating Margin (5Y Avg)28.38%
EPS Excl Extra (Annual)$14.23
CapEx CAGR (5Y)25.03%
Tangible BV CAGR (5Y)-10.56%
26-Week Price Return22.46%
Quick Ratio (Annual)0.90x
13-Week Price Return8.00%
Total Debt / Equity (Annual)6.31x
Current Ratio (Quarterly)1.14x
Enterprise Value$236,628.39
Revenue / Share Growth (5Y)9.49%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)-0.26%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.97x
Pretax Margin (Annual)24.42%
Cash / Share (Annual)$16.94
3-Month Return Std Dev28.76%
Gross Margin (5Y Avg)74.44%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-5.29%
EBITDA Interim CAGR (5Y)-0.52%
ROE (Last FY)89.06%
Net Interest Coverage (Annual)2.20x
EPS Basic Excl Extra (Annual)$14.23
P/FCF (TTM)23.60x
Receivables Turnover (TTM)4.50x
EV / Free Cash Flow (TTM)29.21x
Total Debt / Equity (Quarterly)6.31x
EPS Incl Extra (TTM)$14.23
Receivables Turnover (Annual)4.50x
ROI (TTM)12.11%
Dividend Growth Rate (5Y)9.41%
P/S Ratio (TTM)5.20x
Pretax Margin (5Y Avg)23.95%
Revenue / Share (Annual)$67.81
Tangible BV / Share (Annual)$8.03
Forward P/E15.65x
Free OCF CAGR (5Y)-3.91%
Price vs S&P 500 (52W)-9.39%
P/E Ratio (TTM)24.79x
EPS Growth TTM (YoY)88.56%
Year-to-Date Return8.55%
5-Day Price Return1.57%
EPS Normalized (Annual)$14.23
ROA (5Y Avg)7.91%
Net Profit Margin (Annual)20.98%
Month-to-Date Return0.98%
Cash Flow / Share (TTM)$20.77
EBITD / Share (Annual)$17.91
EPS Growth (3Y)5.51%
Operating Margin (Annual)24.71%
LT Debt / Equity (Annual)5.78x
P/CF (TTM)19.20x
ROI (5Y Avg)11.60%
P/E Excl Extra (TTM)24.79x
LT Debt / Equity (Quarterly)5.78x
EPS Basic Excl Extra (TTM)$14.23
P/TBV (Quarterly)27.47x
Payout Ratio (Annual)118.14%
P/B Ratio (Annual)20.36x
Dividend / Share (TTM)$9.38
Inventory Turnover (TTM)1.48x
Pretax Margin (TTM)24.42%
Book Value / Share (Annual)$16.06
Price vs S&P 500 (13W)5.14%
Net Margin Growth (5Y)-5.99%
Dividend Yield (TTM)2.64%
Beta0.47x
P/FCF (Annual)23.60x
Revenue / Share (TTM)$67.68
ROE (TTM)96.65%
52-Week Low$261.43
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.61
3.59
3.55
3.53
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
HALOHalozyme Therapeutics, Inc. | 5.90x | 37.55% | 83.62% | 22.89% | $69.57 |
About
Amgen is a leading global biotechnology company with a diversified portfolio spanning oncology, cardiovascular disease, immunology, inflammation, and rare diseases. The company has expanded through strategic acquisitions including Onyx Pharmaceuticals and Horizon Therapeutics, while building a growing biosimilar business alongside marketed drugs across multiple therapeutic franchises. Recent launches demonstrate continued innovation in areas including cardiovascular health, migraine, oncology, and immunology.